Research and application of targeting nano-drugs

Nano Biomedicine and Engineering

Volumn 3, Issue 2, 2011, Pages 73-83

  Liu, Chang Xiao ^a,b  

^a TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^b China National Academy of Nanotechnology and Engineering   (China)

Author keywords

Active targeting; Biodistribution; Drug delivery; Nano drug; Passive targeting; Targeting function

Indexed keywords

EID: 80053459506     PISSN: None     EISSN: 21505578     Source Type: Journal    
DOI: 10.5101/nbe.v3i2.p73-83     Document Type: Article

References (85)

1. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol 2008; 229(1):121-34. doi:10.1016/j.taap.2008.02.007
2. Shephard MJ, Todd D, Adair BM, Po ALW, Mackie DP, Scott E.M. Immunogenicity of bovineparainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administra-tion to mice. Res Vet Sci 2003; 74: 187-190. doi:10.1016/S0034-5288(02)00180-7
3. Cui ZR, Mumper RJ. Intranasal administra-tion of plasmid DNAcoated nanoparticles result in en-hanced immune responses. J Pharm Pharmacol 2002; 54: 1195-1203. doi:10.1211/002235702320402035
4. Matsusaki M, Akashi M.Functional multilayered capsules for targeting and local drug delivery. Expert Opin Drug Deliv 2009; 6(11):1207-17. doi:10.1517/17425240903280414
5. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed 2005; 1(3):193-212. doi:10.1016/j.nano.2005.06.004
6. Maeda H. Wu J, Sawa Y, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics:a review. J Control Release 2000; 65: 271-284. doi:10.1016/S0168-3659(99)00248-5
7. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Delivery Rev 2004; 56: 1273-1289.doi:10.1016/j.addr.2003.12.004
8. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Delivery Rev 2002; 54: 235-252. doi:10.1016/S0169-409X(02)00019-4
9. Greco F, Vicent MJ. Polymer-drug conjugates: current status and future trends. Front Biosci 2008; 13:2744-56. doi:10.2741/2882
10. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Releas 2001; 74: 317-323. doi:10.1016/S0168-3659(01)00342-X
11. Du SL, Pan H, Lu WY, Wang J, Wu J, Wang JY. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibros is in rats. J Pharmacol Exp Ther 2007; 322: 560-568. doi:10.1124/jpet.107.122481
12. Briz O, Macias RIR, Vallejo M, Silva A, Serrano MA, Marin JJG. Usefulness of liposomes loaded with cytos tatic bile acid derivatives to circum-vent chemotherapy res is tance of enterohepatic tumors. Mol Pharmacol 2003; 63: 742-750. doi:10.1124/mol.63.3.742
13. aul JM, Annapragada AV, Bellamkonda RV. A dualligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006; 114: 277-287. doi:10.1016j.jconrel. 2006.05.028
14. Hashida M, Akamatsu K, Nishikawa M, Yamashita F, Yoshikawa H, Takakura Y. Design of polymeric prodrugs of PGE1 for cellspecific hepatic targeting. Pharmazie 2000; 55: 202-205.
15. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current prspective and future promise. Pharmacol Ther 2010; 128(2):324-35. doi:10.1016/j.pharmthera.2010.07.007
16. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv 2008; 5(5):567-81. doi:10.1517/17425247.5.5.567
17. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; 2(1):99-112. doi:10.1002/wnan.66
18. Chung JE, Yokoyama M, Aoyagi T, Sakurai Y, Okano T. Effect of molecular architecture of hy-drophobically modified poly (N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers. J Control Release 1998; 53: 119-130. doi:10.1016/S0168-3659(97)00244-7
19. Kohori F, Sakai K, Aoyagi T, Yokoyama M, Sakurai Y, Okano T. Preparation a characterization of thermally responsive block copolymer micelles compris-ing poly (N-isopropylacrylamide-β-DL-lactide). J Control Release 1998; 55: 87-98. doi:10.1016/S0168-3659(98)00023-6
20. Meyer O, Papahadjopoulos D, Leroux JC. Co-polymers of N-isopropylacrylamide can trigger pH sensitivity to stable liposomes FEBS Lett 1998; 421: 61-64. doi:10.1016/S0014-5793(97)01520-2
21. Stover TC, Kim YS, Lowe TL, Keste M. Thermoresponsive and bio-degradable linear-dendritic nanoparticles for targeted and sustained release of a proapoptotic drug. Biomaterials 2008; 29: 359-369. doi:10.1016/j.biomaterials.2007.09.037
22. Na K, Lee ES, Bae YH. Adriamycin loaded pullulan acetate/sulfonamide conjugate nanopar-ticles responding to tumor pH: pHdependent cell inter-action, internalization and cytotoxicity in vitro. J. Control Release 2003; 87: 3-13. doi:10.1016/S0168-3659(02)00345-0
23. Yoo HS, Lee EA, Park TG. Doxorubicin- conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control. Release, 2002; 82: 17-27. doi:10.1016/S0168-3659(02)00088-3
24. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 2007, 35(Pt 1):56-60.
25. Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, Delie F. Nanomedicines for active targeting: physicochemical characterization of paclitaxelloaded anti-HER2 immunonanoparticle and in vitro functional studies on target cells. Eur J Pharm Sci 2009; 38(3):230-7. doi:10.1016/j.ejps.2009.07.006
26. Xiao S., Tong CY, Liu XM, Yu DM, Liu QL, Xue CG, Tang DY, Zhao LJ. Preparation of folate-conjugated starch nanoparticles and its applica-tion to tumor-targeted drug delivery vector. Chin Sci Bull 2006; 51: 1151-1155. doi:10.1007/s11434-006-2039-7
27. Pan J, Feng SS. Targeted delivery of pa clitaxel using folatedecorated poly(lactide)-vitaminE TPGS nan-oparticles. Biomaterials 2008; 29: 2663-2672. doi:10.1016/j.biomaterials.2008.02.020
28. Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).. Int J Nanomedicine 2007; 2(1):39-47. doi:10.2147/nano.2007.2.1.39
29. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloprotei- nase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinomaselective targeting. J Control Release 2006; 111: 333-342. doi:10.1016/j.jconrel.2005.12.023
30. Liang XJ, Chen C, Zhao Y, Jia L, Wang PC. Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Metab 2008; 9(8): 697-709. doi:10.2174/138920008786049230
31. Tang N, Du G, Wang N, Liu C, Hang H, and Liang W. Improving Penetration in Tumors with Nano- assemblies of Phospholipids and Doxorubicin. J Natl Cancer Inst 2007; 99: 1004-1015. doi:10.1093/jnci/djm027
32. Dreher MR, Chilkoti A. Toward a Systems Engineering Approach to Cancer Drug Delivery. J Natl Cancer Inst 2007; 99: 983-985. doi:10.1093/jnci/djm042
33. Wei GL, Xiao SH, Si DY, Liu CX. Comparative pharmacokinetics of micelle- or liposomal encapsulated doxorubicin formulations to healthy rats and tumor-bearing mice. Drug Metabolism Reviews 2008; 40(S2): 81-82. 46.
34. Xu YY, Xiao SH, Wei GL, Liu CX, Si DY. Nanoparticle of doxorubicin eliminate the accumulation in tissues of tumor-bearing mice. Drug Metabolism Reviews 2008; 40(S2):193.
35. Li QS, Cheng TF, Huang YR, Si DY, Liu CX. Comparative pharmacokinetics and tissue distribution between free and Micelle-Encapsulated Alprostadil. Drug Metabolism Reviews 2008; 40(S2): 80-81.
36. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007; 15 (7-8): 457-64. doi:10.1080/10611860701539584
37. Sershen SR, Westcoot SL, Halas NJ, West JL. Temperature-sensitive polymer-nanoshell com-posites for photothermally modulated drug delivery. J Biomed Mater Res 2000; 51: 293-298. doi:10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
38. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995; 83: 1029-1037. doi:10.3171/jns.1995.83.6.1029
39. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol 1998; 8: 164-175. doi:10.1016/S1053-4296(98)80042-8
40. Venturoli D, Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol 2005; 288(4): F605-F613.
41. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U.S.A. 1998; 95: 4607-4612.doi:10.1073/pnas.95.8.4607
42. Qi L, Xu Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg Med Chem Lett 2006; 16: 4243-4245. doi:10.1016/j.bmcl.2006.05.078
43. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumorspecific nanoparticle delivery: effect of particle size. Cancer Res 2000; 60: 4440-4445.
44. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 1996; 13: 245-255. doi:10.3109/02652049609026013
45. Seki J, Sonoke S, Saheki A, Koike T, Fukui H, et al. Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins. Int J Pharm 2004; 275: 239-248. doi:10.1016/j.ijpharm.2004.02.008
46. Foldvari M. Nanomedicine research in Canada. Nanomed 2006; 2(4): 296. doi:10.1016/j.nano.2006.10.088
47. Zhao XJ. Nanomedicine Research in China. Nanomed 2006; 2(4): 297.
48. Wong K. Development of nanomedicine in Hong Kong. Nanomed 2006; 2(4): 297. doi:10.1016/j.nano.2006.10.091
49. Jain NK. Status of nanomedicine research in India. Nanomed 2006; 2(4): 297. doi:10.1016/j.nano.2006.10.092
50. Urisu T, Wei CM. America-Japan Nanomedicine Society (AJNS). Nanomed 2006; 2(4): 297-298. doi:10.1016/j.nano.2006.10.093
51. Lee YS. Current research status of biomedical micro and nano technologies in Korea. Nanomed 2006; 2(4): 298. doi:10.1016/j.nano.2006.10.094
52. Yaminsky I. Outlook into the nanomedicine research in Russia. Nanomed 2006; 2(4): 298. doi:10.1016/j.nano.2006.10.095
53. Yun J. Singapore-an ideal R&D hub for bio-nanotechnology. Nanomed 2006; 2(4): 299.
54. Hunziker P. Nanomedicine Research in Switzerland. Nanomed 2006, 2(4): 299.
55. Donald A. Tomalia. International report on nanomedicine in the U.S.A.. Nanomed 2006; 2(4): 299. doi:10.1016/j.nano.2006.10.098
56. Liang XJ, Chen C, Zhao Y, Jia L, Wang PC. Biopharmaceutics and therapeutic potential of engineered nanomaterials. Curr Drug Meta 2008; 9(8): 697-709. doi:10.2174/138920008786049230
57. Si DY, Sun YD, Cheng TF, Liu CX. Biomedical evaluation of nanomedicines, Asia J Pharmacodyn Pharmacokinet 2007; 7(2): 83- 97.
58. Sun YD, Chen ZM, Wei H, Liu CX. Nanotechnology challenge: safety of nanomaterials and nanomedicines. Asian J Pharmacodyn Pharmacokinet 2007; 7(1): 17-31.
59. Cheng TF, Sun YD, Si DY, Liu CX. Attention on research of pharmacology and toxicology of nanomedicines. Asian J Pharmacodyn Pharmacokinet 2009; 9(1): 25-27.
60. Bai CL. Ascent of Nanoscience in China. Science 2005; 309: 61-63 doi:10.1126/science.1115172
61. Liu, CX. Research and Development of Nanopharmaceuticals in China. Nano Biomed Eng 2009; 1: 1-12. doi:10.5101/nbe.v1i1.p1-12
62. Tian FR, Prina-Mello A, Estrada G, Beyerle A, Möller W, Schulz H, Kreyling W, Stoeger T. Macrophage Cellular Adaptation, Localization and Imaging of Different Size Polystyrene Particles. Nano Biomed Eng 2009; 1(1): 13-26. doi:10.5101/nbe.v1i1.p13-26
63. Xie CJ, Yin DG, Li J, Zhang L, Liu BH, Wu MH. Preparation of a Novel Amino Functionalized Fluorescein-doped Silica Nanoparticle for pH Probe. Nano Biomed Eng 2009; 1(1): 27-31.
64. Li H, Zhang YG, Huang WP. Photoactivation of Ion-exchangeable Trititanate Nanotubes Modified by MS (M = Cd, Zn) Nanoparticles. Nano Biomed Eng 2009; 1(1):32-37.
65. Vishwanathan R, Wilson TA, Nicolosi RJ. Bioavailability of a Nanoemulsion of Lutein is Greater than a Lutein Supplement. Nano Biomed Eng 2009; 1(1): 38-49. doi:10.5101/nbe.v1i1.p38-49
66. Bao CC, Yang H, Sheng P, ong H, Ding XH, Liu B, Lu YC, Hu GH, Cui DX. Cloning, Expression, Monoclonal Antibody Preparation of Human Gene NBEAL1 and Its Application in Targeted Imaging of Mouse Glioma. Nano Biomed Eng 2009; 1(1): 50-56.
67. Liu DW, Chen ZW, Wang X, Xu HZ, Wang L. The Threedimensional Images and Intracellular Calcium Analysis of Weigela Floridacv and Lonicera Japonica Thunb Pollen. Nano Biomed Eng 2009; 1(1): 57-60. doi:10.5101/nbe.v1i1.p57-60
68. Cui DX, Han HD, Li ZM, Song H, Wang K, He R, Liu B, Liu HL, Bao CC, Huang P, Ruan J, Gao F, Yang H, Cho HS, Ren Q, Shi DL. Fluorescent Magnetic Nanoprobes for in vivo Targeted Imaging and Hyperthermia Therapy of Prostate Cancer. Nano Biomed Eng 2009; 1(1): 61-74. doi: 10.5101/nbe.v1i1.p61-74
69. He CL, Zhang L, Wang HS, Zhang F, Mo XM. Physical-chemical Properties and in vitro Biocompatibility Assessment of Spider Silk, Collagen and Polyurethane Nanofiber Scaffolds for Vascular Tissue Engineering. Nano Biomed Eng 2009; 1(1): 80-88. doi:10.5101/nbe.v1i1.p80-88
70. Aslan K. Rapid Whole Blood Bioassays using Microwave-Accelerated Metal-Enhanced Fluorescence. Nano Biomed Eng 2010; 2(1): 1-7. doi:10.5101/nbe.v2i1.p1-7
71. Dada M, Moses OF, Awojoyogbe OB, Boubaker K, Isah K. Investigation of Nano-keyhole Cooling Evolution using Boubaker Polynomials Expansion Scheme (BPES). Nano Biomed Eng 2010; 2(1): 8-14.
72. Chen SH, Ji YX, Lian Q, Wen YL, Shen HB, Nengqin Jia NQ. Gold Nanorods Coated with Multilayer Polyelectrolyte as Intracellular delivery Vector of Antisense Oligonucleotides. Nano Biomed Eng 2010; 2(1): 15-23.
73. Li YQ, Li ZY, Zhou XP, Yang P. Detection of Nano Eu2O3 in Cells and Study of its Biological Effects. Nano Biomed Eng 2010; 2(1): 24-30.doi:10.5101/nbe.v2i1.p24-30
74. Wang T, Hu Y, Zhang L, Jiang L, Chen Z, He NY: Erythropoietin Nanopariticles.Therapy for Cerebral Ischemic Injury and Metabolize in Kidney and Liver. Nano Biomed Eng 2010; 2(1): 31-39.
75. Yin DG, Zhang L, Xie CJ, Liu BH, Zhang L. Preparation and Characterization of DPPDA-Eu3+ Doped Silica Fluorescent Nanoparticles. Nano Biomed Eng 2010; 2(1): 40-44. doi:10.5101/nbe.v2i1.p40-44
76. Cui DX, Li Q, Huang P, Wang K, Kong YF, Zhang H, You XG, He R, Song H, Wang JP, Bao CC, Asahi T, Gao F, Osaka T. Real time PCR based on Fluorescent Quenching of Mercaptoacetic Acid-Modified CdTe Quantum Dots for Ultrasensitive Specific Detection of Nucleic Acids. Nano Biomed Eng 2010; 2(1): 45-55. doi:10.5101/nbe.v2i1.p45-55
77. Chen F, Huang P, Mo XM. Electrospinning of Heparin Encapsulated P(LLA-CL) Core/Shell Nanofibers. Nano Biomed Eng 2010; 2(1): 56-60. doi:10.5101/nbe.v2i1.p56-60
78. Ji JJ, Ruan J, Cui DX. Advances of Nanotechnology in the Stem Cells Research and Development. Nano Biomed Eng 2010; 2(1): 67-90.
79. Cohen-Sela E, Chorny M, Gutman D, Komemi S, Koroukhov N, Golomb G. Characterization of Monocytes-targeted Nanocarriers Biodistribution in Leukocytes in ex-vivo and in-vivo Models. Nano Biomed Eng 2010; 2(2): 91-99.
80. Bagul M, Kakumanu S, Wilson T, Nicolosi R. In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines. Nano Biomed Eng 2010; 2(2): 100-108.
81. Yin DG, Liu BH, Zhang L, Xie CJ, Zhang L. Synthesis of Ru(bpy)3-doped Silica Nanoparticle and Its Application in Fluorescent Immunoassay. Nano Biomed Eng 2010; 2(2): 117-120.
82. Liu J, Zhang B. The Study on Electrochemical Behaviors of the Interactions between Daunorubicin Hydrochloride and BSA. Nano Biomed Eng 2010; (2): 138-142.
83. Liu B, Deng Y, Qin BB, Li ZY, He HY. Biological Application of Digital Microfluidics Technology. Nano Biomed Eng 2010; 2(2): 149-154.
84. Meng C, Xiong YL, Zhuang WL, Wang H, Shi XA, Guo YH. Development of a Rapid and Convenient Method for Sampling Airborne Virus based on Nanoparticle Adsorption. Nano Biomed Eng 2010; 2(3): 171-176.
85. Liu Y, Niu TS, Zhang L, Yang JS. Review on nano-drugs. Natural Science 2010; 2(1):41-48, doi:10.4236/ns.2010.21006